NEW YORK, June 15, 2011 /PRNewswire/ -- NeoStem, Inc. ("NeoStem" or the "Company") (NYSE Amex: NBS), an international biopharmaceutical company with product and service revenues, global research and development capabilities and operations in three distinct business units – U.S. adult stem cells, China adult stem cells, and China pharmaceuticals, announced today that Jason Kolbert, Vice President of Strategic Business Development, will present at the Proactive Investors One2One Investor Forum on June 16. NeoStem will also present at OneMedForumNY 2011 on June 23.
The Proactive Investors One2One Investor Forum will be held at the Denver Omni Hotels and Resorts, 500 Interlocken Boulevard in Denver, Colorado. The presentations will be from 6:00 pm to 7:30 pm MST on Thursday, June 16, 2011. Mr. Kolbert, will update the audience on NeoStem's current position. After the presentation, Mr. Kolbert will take questions during a reception. Those interested in attending the event may register at http://www.proactiveinvestors.com/register/event_details/50.
OneMedForumNY 2011 is the sixth OneMedForum and second in New York and will feature presentations by over 70 emerging medical technology companies. The conference will take place June 23 and 24, 2011 at the Roosevelt Hotel in New York City, 45 East 45th Street at Madison Avenue. NeoStem will present at 11:15 AM EDT on June 23 in the Plaza Room. To register for the event please visit http://www.onemedplace.com/forum/registration.
Jason Kolbert, Vice President of Strategic Business Development said, "NeoStem continues to position itself to be an emerging leader in the paradigm shift to cell-based therapeutics. Our acquisition of Progenitor Cell Therapy ("PCT") provides NeoStem with core expertise to facilitate this transition. Right now we are focused on acquiring assets that are ready for Phase II clinical trials, leveraging PCT's manufacturing and NeoStem's collection model and expertise."
"We look forward to executing on important milestones in the near future and to sharing our vision, progress and current outlook with the investor community," said Dr. Robin L. Smith, NeoStem's Chairman and CEO.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development and manufacturing of cell-based therapies in the U.S. Its January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") is central to the Company's strategic mission of capturing the paradigm shift to cell therapy. The acquisition of PCT gives NeoStem not only access to a world class contract manufacturing cell therapy company but provides a platform and expertise around the evaluation, development and regulatory requirements to develop autologous, allogeneic, immunomodulatory and vaccine-based therapeutics. NeoStem also holds the worldwide exclusive license to VSEL(TM) Technology, which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem owns 80% of Athelos Corporation, a company developing a T-cell therapeutic with potential in a range of auto-immune conditions such as graft versus host disease, asthma and diabetes. Furthermore, NeoStem is building its Chinese presence by establishing an operations lab for cell-based manufacturing in Beijing as well as commercializing cellular therapies in China through the establishment of a network of hospitals. NeoStem also owns a majority-interest in Suzhou Erye Pharmaceutical Company Limited, a world class manufacturing and distribution operation of generic antibiotics in China.
For more information, please visit: http://www.neostem.com.
About The Proactive Investors One2One Investor Forum
The Proactive Investors group operates a successful "investor forums" where three or four companies present to an audience of high net sophisticated investors, fund managers, hedge funds, private client brokers and analysts. Proactive Investors is a leading multi-media news organization, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London. Proactive Investors operates five financial websites in four languages providing breaking news, comment and analysis on hundreds of listed companies across the globe daily.
For more information, please visit http://www.proactiveinvestors.com.
OneMedPlace (OMP) is a New York based healthcare research and media company that manages a business development platform to help emerging healthcare and life sciences companies maximize their potential. OMP offers an innovative and powerful suite of services to globally connect investors and strategic partners to the companies shaping the future of health and medicine.
OMP provides to strategic and financial investors efficient access to information about high potential opportunities around the world through an integrated set of tools including:
OneMedDatabase: Over 8,000 companies and resources.
OneMedForum : a biannual business development and investment conferences in San Francisco (January) and New York City (June).
OneMedTV: Documentaries on promising companies and technologies as well as coverage of thought leaders and the important healthcare events.
Sentinel: weekly e-newsletter tracking the major trends and the companies involved.
For more information, please visit http://www.onemedplace.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful execution of the Company's strategy, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 6, 2011, as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
For more information, please contact:
|SOURCE NeoStem, Inc.|
Copyright©2010 PR Newswire.
All rights reserved